Abstract
The problem of dosing drugs at an early age is conditioned by specific metabolism of medicinal products (MP) in the child's body. Currently, there are a few clinical trials on the study of physiological characteristics in different periods of childhood and systematised data. It is still relevant to understand the characteristic differences that affect the bioavailability, distribution and excretion of MP, especially in children over one month of life. The results of such studies are necessary in order to formulate the recommendations for use of MP in children taking into account their age and compensate for the lack of data from direct clinical trials in pediatrics. The possibility of using a dose calculation method regarding the fat content of the body in different periods of childhood and the chemical properties of the substance has been discussed.
Highlights
ВВЕДЕНИЕ На сегодняшний день благодаря оригинальным клиническим исследованиям для каждого лекарственного препарата, разрешенного к медицинскому применению, нам известны его фармакокинетические и фармакодинамические параметры, эффективность, профиль безопасности и оптимальные режимы дозирования
The problem of dosing drugs at an early age is conditioned by specific metabolism of medicinal products (MP) in the child's body
It is still relevant to understand the characteristic differences that affect the bioavailability, distribution and excretion of MP, especially in children over one month of life. The results of such studies are necessary in order to formulate the recommendations for use of MP in children taking into account their age and compensate for the lack of data from direct clinical trials in pediatrics
Summary
Результаты таких исследований необходимы для формирования рекомендаций по применению ЛС у детей с учетом их возраста и компенсации отсутствия данных прямых клинических исследований в педиатрии. It is still relevant to understand the characteristic differences that affect the bioavailability, distribution and excretion of MP, especially in children over one month of life The results of such studies are necessary in order to formulate the recommendations for use of MP in children taking into account their age and compensate for the lack of data from direct clinical trials in pediatrics. ОСОБЕННОСТИ ФАРМАКОКИНЕТИКИ И ФАРМАКОДИНАМИКИ ЛЕКАРСТВЕННЫХ СРЕДСТВ В РАЗЛИЧНЫЕ ПЕРИОДЫ ДЕТСКОГО ВОЗРАСТА Применительно к детям чаще используется два принципиально важных для расчета доз ЛС показателя — масса тела и площадь поверхности тела. Features of pharmacokinetics of medicinal products in different periods of childhood [12]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
